GPT and metabolic dysfunction-associated steatohepatitis: When using Criteria 1, the prevalence of F3/F4 fibrosis among NASH patients increased significantly from 7.82% in patients with elevated ALT and one metabolic co-morbidity to 11.63% to NASH patients with elevated ALT and four concurrent metabolic co-morbidities, p<0.001.